Research Solutions (RSSS) delivered a quarter that looks better on the earnings line than in the growth metrics underneath it. Fiscal first-quarter earnings of $0.04 per share beat the $0.02 consensus by 100.0% and grew 100.0% year over year. Revenue of $11.91 million missed the $11.99 million consensus by 0.7% and fell 3.2% from a year ago. The central tension is clear: management produced its most confident AI narrative yet, with a record deal and a pipeline above $5 million of ARR, while reported recurring growth decelerated for another quarter and full-year adjusted EBITDA expectations moved lower.
The quality of the beat deserves scrutiny. The $0.04 figure is adjusted net income excluding one-time items. On a GAAP basis, the company earned $765,000, or $0.02 per diluted share, essentially unchanged from $749,000 a year ago. Even that GAAP result was helped by a non-cash stock-compensation recovery from restricted stock forfeitures, which turned the line into a credit of roughly $197,000 versus a $212,000 expense last year. G&A rose 32.8% on legal and severance costs. Adjusted EBITDA fell 30.3% to $1.0 million, an 8.6% margin, or $1.5 million excluding one-time items, roughly flat with last year. The real operating improvement came at the gross line. Gross margin expanded 300 basis points to 53.6%, driven by mix shift and a transaction margin that rose to 26.7% from 23.8%. That more than offset a dip in platform gross margin to 87.0% from 88.1% as hosting costs rose.
The deceleration shows up in the recurring business. Platform revenue grew just 3.7%, down from 7% growth cited on the prior call and 14% two quarters earlier. Total ARR growth slowed to 5.7% from 8.5% and 14%. B2B ARR still grew 11.5% to $16.5 million, but incremental B2B ARR in the quarter was only $257,000, less than half the $561,000 added a year ago. Management put Q1 B2B bookings at about $500,000. The call cited the prior quarter at roughly $961,000 in one context and about $1.3 million in another, but either figure marks a steep sequential drop. B2C ARR fell another $299,000 to about $6.0 million. Churn is down about 30% from a year ago but remains near $300,000 a quarter, which management called its biggest pain point. Transaction revenue declined 8.2% on lower paid order volume even as active customers rose to 1,360, with academic accounts up 17% and corporate accounts down 2.1%. Management said part of that weakness is unexplained and acknowledged that AI "zero-click" substitution is possible. That is a meaningful admission for a business built on article access.
The forward story is where the call gained conviction. After the quarter closed, the company signed the largest deal in its history: a roughly $1 million ARR Scite expansion with a long-time Article Galaxy customer. It will book in Q2 on a one-year term, with potential upside in years two and three. Management described the pipeline, now above $5 million of ARR, as its strongest ever, including another roughly $1 million pharma opportunity. Several AI metrics are moving quickly:
- AI-related ARR reached about $1.1 million, up 38% since fiscal year-end.
- Customers with AI in their contracts rose to 49 from 42.
- AI reads doubled to more than 33 million after integrations with ChatGPT, Claude and now Microsoft Copilot.
- Researchers at more than 15 corporate customers placed hundreds of orders through AI assistants in October, up from a few dozen per month over the summer.
The costs and timing pressures are equally concrete. The big deal slipping a quarter, plus severance, legal and IT security spending that will continue into Q2, led management to say full-year adjusted EBITDA will come in a little lower than previously discussed. Management added that the exit run-rate should exceed its prior view. Large-deal sales cycles have stretched to five to seven months or longer amid AI and security reviews. Sales and marketing spending is also set to rise by $100,000 to $200,000.
The balance sheet gives management room to execute. Cash was $12.6 million with no debt after a $1.2 million Scite earn-out payment, though about $5.6 million of contingent earn-out liability remains. The board views buybacks as the best use of cash and flagged a possible announcement.
Investor sentiment remains deeply negative but improved, rising to -0.78 from -0.93 before the prior report. The stock has not reflected that thaw. Shares at $1.89 are down 11.7% since the open following the last report and sit 16.4% below the 200-day moving average of $2.26. Earnings Whispers price and AVWAP trend readings are both negative.
The bottom line is that Research Solutions offered a credible AI-monetization story, with a record deal, a much larger pipeline and agentic ordering gaining traction. However, the reported numbers are moving the other way: slowing ARR growth, thin bookings, eroding transactions and B2C, and a softer EBITDA outlook. The adjusted EPS beat does little to resolve that gap. Investors will need to see the $1 million deal and pipeline conversion show up in Q2 net-new ARR before the improving narrative can outweigh the decelerating results.